Condition: Gout · Sponsor: Shanghai Institute Of Biological Products
To evaluate the safety and tolerability of peguricase for injection with methotrexate in patients with gout who remain uncontrolled after standardized treatment with conventional uric acid-lowering drugs, to determine the recommended dose for phase II clinical trials, and to provide basis for formulation of administration regimen for phase II clinical trials.
This description comes directly from the study's public registry record.
Dandan Chen, Master · 86-021-62800991 · ddchen.sh@sinopharm.com
Chaorong Xu, Master · 86-021-62800991 · xuchaorong@sinopharm.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Bengbu Medical College | Bengbu, Anhui, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06298071